A systematic review and meta-analysis evaluated the risk for obesity-related cancer associated with glucagon-like peptide-1 ...

What if the race to get thin was quietly putting health at risk? That question is becoming harder to ignore as glucagon‑like ...

For patients with type 2 diabetes, there is an association between glucagon-like peptide-1 receptor agonist (GLP-1 RA) use ...

(HealthDay News) — The oral small-molecule glucagon-like peptide 1 (GLP-1) receptor agonist orforglipron demonstrates superior weight loss as an adjunct to lifestyle modification versus placebo for ...

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are increasingly used for postpartum weight loss since the introduction of ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related ...

GLP-1 medicines cause malnutrition in 22% of patients. Multivitamins are often inadequate. Patients need dietitian support ...

MASLD is one of the pressing public health issues; yet, unfortunately, there is a scarcity of available pharmacological management options. GLP-1RAs have transformed the treatment landscape for ...

The National Academies’ Forum on Neuroscience and Nervous Systems Disorders hosted a workshop on September 10, 2024, they brought together diverse perspectives to examine the promising but ...

Oxyntomodulin (OXM) is a peptide hormone released by intestinal L cells after food intake. It acts as a dual agonist of glucagon-like peptide 1 (GLP-1) and glucagon receptors, regulating appetite, ...

About The Study: In this cohort study, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among patients with diabetes was associated with a 2-fold higher risk of incident neovascular ...

The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide expert advice on some of the most pressing challenges facing the nation and world. Our ...